Access To Success: The Second Annual UCBeyond Scholarship Program
- Fulfilling Dreams for Students Living With Crohn’s Disease and Rheumatoid Arthritis -
February 27, 2008 (Burlington, ON) — UCB Pharma Canada is pleased to announce the
return of the UCBeyond Crohn's Disease and Rheumatoid Arthritis Scholarship Program, the
first and only scholarships of their kind in Canada.
“This scholarship, quite simply, has changed my life,” says Laura Bradbury, recipient of a
2007 UCBeyond Crohn’s Disease Scholarship. “Completing my post-secondary schooling has
always been a goal for me, and the UCBeyond Scholarship Program has given me the
opportunity to achieve it.”
Obtaining a good education - an important goal for most Canadians - is hard enough to attain
without dealing with a chronic illness. With the objective of making education an achievable
goal for students living with Crohn's Disease and Rheumatoid Arthritis, UCB Pharma Canada
is committed to offering the UCBeyond Scholarship Program again in 2008.
“UCB is dedicated to creating unique programs and tools to aid patients in reaching above
and beyond the boundaries of their disease and fulfilling their educational ambitions,” says
Rob Hamilton, President of UCB Pharma Canada. “We are proud of the 14 recipients who
have already furthered their post-secondary education through these scholarships, and we
look forward to even more participation across Canada in 2008. Not only do the scholarships
create incredible opportunities, but also great awareness of these diseases.”
The UCBeyond Scholarship Program will award seven (7), one-time scholarships of up to
$5,000 CDN each to people diagnosed with Crohn's disease and seven (7), one-time
scholarships of up to $5,000 CDN each to people diagnosed with rheumatoid arthritis. The
winners must demonstrate academic ambition and use their scholarship toward post-
secondary education (i.e. university, college, trade school, etc.) for the 2008/09 school year.
An independent selection committee of leading physicians and patient representatives from
across the country will again choose the 2008 UCBeyond Scholarship recipients. Applicants
will be evaluated based on a one-page essay demonstrating how they go above and beyond
their disease, exhibit perseverance and empower others, as well as two letters of personal
recommendation. The deadline to apply is June 30, and winners will be announced in
"Congratulations and continued success to UCB with this program! Overcoming the effects of
Inflammatory Bowel Disease (IBD), rather than letting it control you, can be an extremely
difficult task. Students who demonstrated an ability to accomplish this exceptional feat were
recognized in 2007, and we are delighted that these scholarships will continue in 2008,” says
Dr. Kevin Glasgow, CEO of the Crohn’s and Colitis Foundation of Canada - a voluntary, not-
for-profit, medical research foundation dedicated to finding the cure for IBD and one of the
world’s leading sources of non-governmental, funding of IBD research.
“The day a person gets diagnosed with rheumatoid arthritis their opportunity to achieve all that
they want to in life is significantly challenged,” says Cheryl Koehn, President of Arthritis
Consumer Experts (ACE), and a volunteer member of the rheumatoid arthritis scholarship
selection committee. “That is why the UCBeyond Scholarship Program is so valuable to the
arthritis community – it has made a dramatic impact in the lives of those living with rheumatoid
arthritis and provides them with the chance to pursue their educational goals and empowers
them to overcome the obstacles the disease imposes on their lives.”
Other proud supporters of the UCBeyond Scholarship Program include: The Arthritis Society
(TAS), the Canadian Rheumatology Association (CRA), the Canadian Arthritis Patient Alliance
(CAPA) and the Canadian Association of Gastroenterology (CAG).
Students interested in applying for the 2008 UCBeyond Crohn’s Disease and Rheumatoid
Arthritis Scholarship Program can obtain an application package from their gastroenterologist
or rheumatologist, or visit www.ccfc.ca, www.arthritis.ca or www.chromecommunications.ca
for a downloadable application form.
About Inflammatory Bowel Disease
IBD is a chronic and debilitating disease affecting nearly 200,000 Canadians. It includes two
similar yet distinct conditions called Crohn’s disease and ulcerative colitis. These diseases
affect the digestive system and cause the intestinal tissue to become inflamed, form sores
and bleed easily. Symptoms include abdominal pain, cramping, fatigue and diarrhea. Most
people are diagnosed before the age of 30.
Crohn’s Disease can affect any part of the gastrointestinal tract, from the mouth to the anus.
Patches of inflammation occur, leaving healthy tissue between the diseased areas. The
inflammation can extend through several layers of affected tissue. Crohn’s disease cannot be
cured by drugs or surgery, although either or both can help relieve symptoms.
Ulcerative colitis affects only the inner layer of the colon, or large bowel. It always starts in
the rectum and may extend as a continuous inflammation from there into the rest of the colon.
The disease can be completely eliminated by surgically removing part or parts of the colon.
After such surgery, waste material may have to be stored and expelled through an external
The course of IBD is unpredictable. Most people experience periods of remission between
flare-ups of the disease. Frequent or severe flare-ups can require long-term medication,
hospitalisation or surgery. Although IBD is found throughout the world, it is more common
among North Americans and northern Europeans. Canada has among the highest national
rates of incidence and prevalence of Crohn’s disease and ulcerative colitis in the world.
About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a progressive autoimmune disease which causes chronic
inflammation of the joints. It is estimated that 320,000 (1 in 100) people suffer from RA in
Canada.3 Prevalence is not split evenly between genders, since women are three times more
likely to be affected than men.4
Although it can affect people of all ages, the onset of RA usually occurs between 25-50
years.5 Symptoms of RA may include joint stiffness, joint pain, inflammation of the affected
areas and an associated reduction in mobility. These symptoms can be intermittent and vary
in severity from patient to patient. In more severe cases RA can eventually lead to disability.
RA patients are also at a higher risk of developing other conditions, in particular heart
disease, stroke, infections, lung problems and osteoporosis.6
UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical
industry dedicated to the research, development and commercialisation of innovative
pharmaceutical and biotechnology products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses
on securing a leading position in severe disease categories. Employing around 12,000 people
in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis.
UCB S.A. is listed on Euronext Brussels. SCHWARZ PHARMA AG (Monheim, Germany) is a
member of the UCB Group.
About UCB Pharma Canada
UCB Pharma Canada was officially incorporated in 2006 with the objective of bringing a new-
generation, convenient therapy to the Canadian market for auto-immune, inflammatory
diseases. As a patient-focused organization, UCB Pharma Canada’s is dedicated to bringing
new and innovative programs to patients, and to the specialists who treat them, to help
improve the lives of people living with severe diseases.
For more information on the UCBeyond Scholarship Program, please contact:
Chrome Communications, 905-567-1406:
Mark Wigmore, ext. 224; (416) 778-5904 or Tiana DiMichele, ext. 225; (416) 666-5331
1. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis:
Correlation of radiographic, clinical and laboratory abnormalities. Arthritis & Rheumatism , 1971, Vol. 14, No. 6.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of
Rheumatoid Arthritis 2002 update. Arthritis & Rheumatism, 2002 Vol. 46, No. 2.
4. Panayi G What is RA? National Rheumatoid Arthritis Society, June 2006
5. Hellier, J et al, HLA-DRB1 genes and patients with late onset rheumatoid arthritis, Annals of Rheumatic Disease, 2001;60:531-
6. Firestein G, Rheumatoid Arthritis, ACP Medicine WebMD Publishing, August 2004